Medigene Immunotherapies Gmbh

Regeneron Pharmaceuticals, Inc.

Fred Hutchinson Cancer Center

Daniel Sommermeyer

Christian Ellinger

Slavoljub Milosevic

Jasdeep Mann

Marie Bleakley

Robson Dossa

Anna Schleicher

Aline Bracher

Geoffrey Parsons

Geoffrey Blackburn Parsons

The present invention relates to an isolated T cell receptor (TCR) specific for MAGE-A4 and a polypeptide comprising a functional portion of the TCR. Further implicated are a multivalent TCR complex, a nucleic acid encoding a TCR, a cell expressing the TCR and a pharmaceutical composition comprising the TCR. The invention also refers to the TCR for use as a medicament, in particular to the TCR for use in the treatment of cancer.

Mage A4 T cell receptors

The present invention covers an isolated T cell receptor (TCR) specific for one allelic variant of minor histocompatibility antigen 1 (HA-1), in particular the allelic variant HA-1. An isolated polypeptide comprising a functional portion of the TCR is also described. Moreover, a multivalent TCR complex, nucleic acid molecules, vectors, cells, antibodies as well as medical uses that relate to the TCR are defined.

HA-1 specific T cell receptors and their use

The present invention describes methods and uses of antibodies targeting the Cβ1 or the Cβ2 chain of a TCR, in particular an anti-Cβ1 antibody, for enrichment of T cells expressing a desired antigen-specific recombinant T cell receptor (TCR).

Enrichment of T cells using an anti-Cß antibody

The present disclosure provides compositions and methods for targeting a minor histocompatibility (H) antigen (HA-1) to, for example, prevent or manage relapse of a hematological malignancy after allogeneic hematopoietic stem cell transplantation (HCT). Also provided are transgene constructs encoding engineered binding proteins, such as a T cell receptor or a chimeric antigen receptor, optionally encoding additional components such as a co-receptor and/or safety switch. Such transgene constructs can be transduced into an immune cell, such as a T cell, and used as an immunotherapy in a subject having a hematological malignancy or at risk for recurrence of the hematological malignancy (e.g., leukemia, lymphoma, myeloma).

TCRS specific for minor histocompatibility (H) antigen HA-1 and uses thereof

Growing community of inventors

Munich, Germany

Daniel Sommermeyer